drugset / Trial / NCT01615393
A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers
RandomizedCrossoverSingle-blind
Summary
This prospective, randomized, single-blind, cross-over study will compare the bioavailability of Copegus (ribavirin) administered as tablets and ribavirin administered as capsules in healthy volunteers. Volunteers will be randomized to receive a single dose of 400 mg of ribavirin either as a capsule or as tablets; after a washout phase volunteers will be crossed-over to the other treatment. The anticipated time on study treatment is 10 days.
Timeline
- Start
- 2011-06
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ribavirin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.